ArticleJournal of the National Cancer Institute2015
Estrogen Receptor Status and the Future Burden of Invasive and In Situ Breast Cancers in the United States.
Article in Journal of the National Cancer Institute, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 93 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
93 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Adjuvant endocrine therapy and risk of contralateral breast cancer: a systematic review and meta-analysis of observational studies.Cancer causes & control : CCC · 2025Pooled it
- Light at night exposure and risk of breast cancer: a meta-analysis of observational studies.Frontiers in public health · 2023Pooled it
- The prognostic and predictive impact of low estrogen receptor expression in early breast cancer: a systematic review and meta-analysis.ESMO open · 2021Pooled it
- The association between age and lymph node status among patients with breast cancer after neoadjuvant chemotherapy: Eastern European population-based retrospective cohort study.Journal of cancer research and clinical oncology · 2026Article
- County-level socioeconomic status, rurality, and second primary cancer risk among breast cancer survivors in the United States.Cancer causes & control : CCC · 2025Article
- Genetic regulation of the estrogen receptor and inherited predisposition to breast cancer.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- ATE1 promotes breast cancer progression via arginylation-dependent regulation of MAPK-MYC signaling.Cell communication and signaling : CCS · 2025Article
- Landscape of metabolic alterations and treatment strategies in breast cancer.Genes & diseases · 2025Review
- Independent effects of mental health disorders on breast cancer and their mediating factors: evidence from NHANES and two-step Mendelian randomization.Discover oncology · 2025Article
- Investigation of TMEM41A's function in breast cancer prognosis and its connection to immune cell infiltration.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Article
- The Age-Old Question in Nipple-Sparing Mastectomy: Is Older Age a Contraindication?Annals of surgical oncology · 2025Article
- Achieving treatment goals in older breast cancer patients receiving neoadjuvant chemotherapy.Scientific reports · 2025Article
- Forecasting cancer incidence and prevalence using age-period-cohort and survivorship models: a practical, flexible, and interpretable framework.Frontiers in oncology · 2025Article
- Risk of second primary cancer in young breast cancer survivors: an important yet overlooked issue.Therapeutic advances in medical oncology · 2025Review
- Adherence to Aromatase Inhibitor Therapy in Breast Cancer: Insights From a Multicenter Italian Study.The breast journal · 2025Article
- Segmentation for mammography classification utilizing deep convolutional neural network.BMC medical imaging · 2024Article
- ASO Author Reflections: Investigating the Role of Sentinel Lymph Node Biopsy in Older Patients with Triple-Negative Breast Cancer.Annals of surgical oncology · 2024Article
- Triple-Negative Breast Cancer in Older Patients: Does SLNB Guide Therapy?Annals of surgical oncology · 2024Article
- Trends in the incidence and survival of women with hormone receptor-positive breast cancer from 1990 to 2019: a large population-based analysis.Scientific reports · 2024Article
- Intensity-modulated proton radiotherapy spares musculoskeletal structures in regional nodal irradiation for breast cancer: a dosimetric comparison.Acta oncologica (Stockholm, Sweden) · 2024Article
33 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundNo study has predicted the future incidence rate and annual burden (number) of new cases in the United States of invasive and in situ female breast cancers stratified by the estrogen receptor (ER) status.
methodsWe constructed forecasts for women age 30 to 84 years in 2011 through 2030 using cancer incidence data from the Surveillance, Epidemiology, and End Results Program, novel age-period-cohort forecasting models, and population projections from the US Census Bureau.
resultsThe total number of new tumors (invasive plus in situ) is expected to rise from 283 000 in 2011 to 441 000 in 2030 (plausible range 353 500 to 466 700 cases). The proportion of all new case patients age 70 to 84 years is expected to increase from 24.3% to 34.8%, while the proportion ages 50 to 69 years is expected to decrease from 54.7% to 43.6%. The proportion of ER-positive invasive cancers is expected to remain nearly the same at 62.6%, whereas the proportion of ER-positive in situ cancers is expected to increase from 19.1% to 28.9%. The proportion of ER-negative cancers (invasive and in situ) is expected to decrease from 16.8% to 8.6%.
conclusionsBreast cancer overall will rise in the United States through 2030, especially for ER-positive in situ tumors among women age 70 to 84 years. In contrast, ER-negative invasive and in situ tumors will fall, for reasons that are not fully understood. These results highlight a need to optimize case management among older women, characterize the natural history of in situ cancers, and identify those factors responsible for declining ER-negative incidence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.